c-JUN is a barrier in hESC to cardiomyocyte transition.


Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
11 2023
Historique:
received: 27 04 2023
revised: 06 08 2023
accepted: 07 08 2023
medline: 23 8 2023
pubmed: 22 8 2023
entrez: 21 8 2023
Statut: epublish

Résumé

Loss of c-JUN leads to early mouse embryonic death, possibly because of a failure to develop a normal cardiac system. How c-JUN regulates human cardiomyocyte cell fate remains unknown. Here, we used the in vitro differentiation of human pluripotent stem cells into cardiomyocytes to study the role of c-JUN. Surprisingly, the knockout of c-JUN improved cardiomyocyte generation, as determined by the number of TNNT2+ cells. ATAC-seq data showed that the c-JUN defect led to increased chromatin accessibility on critical regulatory elements related to cardiomyocyte development. ChIP-seq data showed that the knockout c-JUN increased RBBP5 and SETD1B expression, leading to improved H3K4me3 deposition on key genes that regulate cardiogenesis. The c-JUN KO phenotype could be copied using the histone demethylase inhibitor CPI-455, which also up-regulated H3K4me3 levels and increased cardiomyocyte generation. Single-cell RNA-seq data defined three cell branches, and knockout c-JUN activated more regulons that are related to cardiogenesis. In summary, our data demonstrated that c-JUN could regulate cardiomyocyte cell fate by modulating H3K4me3 modification and chromatin accessibility and shed light on how c-JUN regulates heart development in humans.

Identifiants

pubmed: 37604584
pii: 6/11/e202302121
doi: 10.26508/lsa.202302121
pmc: PMC10442936
pii:
doi:

Substances chimiques

Chromatin 0
JUN protein, human 0
Proto-Oncogene Proteins c-jun 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023 Zhong et al.

Références

Cell Res. 2013 Oct;23(10):1172-86
pubmed: 24018375
Cell Stem Cell. 2012 Jan 6;10(1):16-28
pubmed: 22226352
Cell Stem Cell. 2008 Jul 3;3(1):55-68
pubmed: 18593559
Signal Transduct Target Ther. 2022 Jun 25;7(1):200
pubmed: 35752619
Nat Methods. 2017 Nov;14(11):1083-1086
pubmed: 28991892
Nat Genet. 2019 Jun;51(6):999-1010
pubmed: 31110351
Genes Dev. 2011 Apr 1;25(7):661-72
pubmed: 21460034
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Nat Biotechnol. 2013 Jul;31(7):615-22
pubmed: 23770639
Front Cell Dev Biol. 2021 Nov 25;9:793605
pubmed: 34901033
Nat Cell Biol. 2009 Aug;11(8):951-7
pubmed: 19620969
Circ Res. 2010 Dec 10;107(12):1414-27
pubmed: 21148448
Circ Res. 2020 Jun 5;126(12):1760-1778
pubmed: 32312172
Nat Commun. 2015 Sep 10;6:8243
pubmed: 26354680
Cell Stem Cell. 2011 Jul 8;9(1):24-36
pubmed: 21726831
BMC Bioinformatics. 2011 Dec 17;12:480
pubmed: 22177264
Dev Cell. 2003 Dec;5(6):877-89
pubmed: 14667410
PLoS One. 2013 Sep 10;8(9):e73294
pubmed: 24039904
Circ Res. 2012 Jul 20;111(3):344-58
pubmed: 22821908
Cell Stem Cell. 2019 Jul 3;25(1):87-102.e9
pubmed: 31271750
J Mol Cell Cardiol. 2021 Oct;159:120-129
pubmed: 34175302
Cell. 2016 Feb 25;164(5):999-1014
pubmed: 26875865
Nature. 1993 Sep 9;365(6442):179-81
pubmed: 8371760
Nucleic Acids Res. 2017 Mar 17;45(5):2354-2367
pubmed: 28426095
Mol Cell. 2011 Jul 8;43(1):145-55
pubmed: 21726817
Circ Res. 2018 Sep 14;123(7):773-786
pubmed: 30355081
Genome Biol. 2014;15(12):550
pubmed: 25516281
Development. 2014 Feb;141(4):878-88
pubmed: 24496624
Nat Commun. 2018 Nov 19;9(1):4877
pubmed: 30451828
Genes Dev. 1993 Jul;7(7B):1309-17
pubmed: 8330736
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5588-93
pubmed: 23487791
Genome Biol. 2010;11(2):R14
pubmed: 20132535
Science. 2020 Jan 24;367(6476):405-411
pubmed: 31974247
Science. 2020 Sep 4;369(6508):
pubmed: 32883834
Circ Res. 2017 Jun 9;120(12):1958-1968
pubmed: 28596174
Mol Cell. 2017 Dec 21;68(6):1067-1082.e12
pubmed: 29272704
Cell Regen. 2014 Jan 24;3(1):1
pubmed: 25408880
Nat Cell Biol. 2015 Jul;17(7):856-67
pubmed: 26098572
Cell Stem Cell. 2017 Dec 7;21(6):819-833.e6
pubmed: 29220666
Curr Protoc Mol Biol. 2015 Jan 05;109:21.29.1-21.29.9
pubmed: 25559105
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
Cell. 2012 Feb 3;148(3):473-86
pubmed: 22304916
Mol Cell. 2017 Sep 21;67(6):1037-1048.e6
pubmed: 28890333
Nat Protoc. 2013 Jan;8(1):162-75
pubmed: 23257984
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Exp Mol Med. 2022 Dec;54(12):2175-2187
pubmed: 36481938
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
J Cell Biol. 1999 May 31;145(5):1049-61
pubmed: 10352021
Sci Adv. 2022 Mar 11;8(10):eabg0834
pubmed: 35275720
Nat Protoc. 2020 Jul;15(7):2247-2276
pubmed: 32561888
Cell Stem Cell. 2019 Jul 3;25(1):149-164.e9
pubmed: 31230860
Nat Methods. 2015 Jul;12(7):595-6
pubmed: 26125590
Science. 2016 Jun 3;352(6290):1216-20
pubmed: 27127239
Circ Res. 2012 Jun 22;111(1):50-5
pubmed: 22581928

Auteurs

Hui Zhong (H)

Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
CAS Key Laboratory of Regenerative Biology, Center for Cell Lineage and Development, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.

Ran Zhang (R)

Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
https://ror.org/00zat6v61 Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Bioland Laboratory Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China.

Guihuan Li (G)

https://ror.org/00zat6v61 Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Ping Huang (P)

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, P.R. China.

Yudan Zhang (Y)

Bioland Laboratory Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China.

Jieying Zhu (J)

CAS Key Laboratory of Regenerative Biology, Center for Cell Lineage and Development, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.

Junqi Kuang (J)

Laboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China.

Andrew P Hutchins (AP)

Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China.

Dajiang Qin (D)

https://ror.org/00zat6v61 Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China tanganqier@163.com.
Bioland Laboratory Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China.
Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences; Hong Kong, China.

Ping Zhu (P)

Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Pathogenesis, Targeted Prevention and Treatment of Heart Disease and Guangzhou Key Laboratory of Pathogenesis, Targeted Prevention and Treatment of Heart Disease, Guangzhou, China.

Duanqing Pei (D)

Laboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China peiduanqing@westlake.edu.cn.

Dongwei Li (D)

Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China lidongwei@gzhmu.edu.cn.
https://ror.org/00zat6v61 Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH